A new international study has delivered a rare dose of good news in the fight against aggressive brain tumors. Researchers found that a drug combination helped adults with recurrent grade 3 ...
Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an ...
IDH-mutant, grade 3 astrocytoma is a serious condition, and many of these tumors return even after aggressive, upfront treatment. By adding a newer, targeted therapy aimed at the underlying IDH ...
– OS and PFS Study endpoints met in large subgroup of patients with recurrent astrocytoma, IDH mutant grade 3 as defined by the 2021 WHO CNS Tumor Classification in Orbus Therapeutics’ Phase 3 STELLAR ...
Eflornithine plus lomustine improved survival in recurrent grade 3 IDH-mutant astrocytoma compared to lomustine alone, with significant gains in progression-free and overall survival. The STELLAR ...
This type of brain tumor can range from slow-growing to highly aggressive forms. Learn how astrocytomas are diagnosed and treated and what factors influence a person’s outlook and recovery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results